Rep. Gilbert Ray Cisneros, Jr. Buys Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock

10 Apr 2026, 21:08 by Kim Johansen · The Markets Daily

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Arcutis Biotherapeutics stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Arcutis Biotherapeutics Trading Down 1.5%

Shares of Arcutis Biotherapeutics stock traded down $0.36 during trading on Friday, reaching $24.21. The company’s stock had a trading volume of 894,690 shares, compared to its average volume of 1,401,654. Arcutis Biotherapeutics, Inc. has a 52-week low of $11.86 and a 52-week high of $31.77. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -172.92 and a beta of 1.76. The firm’s 50-day moving average is $24.66 and its two-hundred day moving average is $25.19. The company has a quick ratio of 2.99, a current ratio of 3.17 and a debt-to-equity ratio of 0.57.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.10. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. The company had revenue of $129.50 million during the quarter, compared to analysts’ expectations of $110.79 million. On average, sell-side analysts anticipate that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current year.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC boosted its position in Arcutis Biotherapeutics by 10.3% during the 3rd quarter. Jennison Associates LLC now owns 12,254,119 shares of the company’s stock valued at $230,990,000 after buying an additional 1,144,714 shares during the period. Suvretta Capital Management LLC lifted its position in shares of Arcutis Biotherapeutics by 14.2% in the 4th quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock worth $347,435,000 after purchasing an additional 1,486,000 shares during the period. Frazier Life Sciences Management L.P. lifted its position in shares of Arcutis Biotherapeutics by 12.4% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 9,874,511 shares of the company’s stock worth $138,441,000 after purchasing an additional 1,089,227 shares during the period. Vanguard Group Inc. lifted its position in shares of Arcutis Biotherapeutics by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 7,253,936 shares of the company’s stock worth $210,654,000 after purchasing an additional 107,846 shares during the period. Finally, Polar Capital Holdings Plc lifted its position in shares of Arcutis Biotherapeutics by 4.9% in the 4th quarter. Polar Capital Holdings Plc now owns 5,556,169 shares of the company’s stock worth $161,351,000 after purchasing an additional 257,415 shares during the period.

Insider Transactions at Arcutis Biotherapeutics

In other news, insider Masaru Matsuda sold 8,733 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $25.30, for a total value of $220,944.90. Following the completion of the sale, the insider directly owned 136,932 shares of the company’s stock, valued at approximately $3,464,379.60. This trade represents a 6.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Larry Todd Edwards sold 3,687 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $25.18, for a total transaction of $92,838.66. Following the completion of the sale, the insider directly owned 175,178 shares of the company’s stock, valued at approximately $4,410,982.04. This represents a 2.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 159,546 shares of company stock worth $4,032,162. 9.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Guggenheim increased their price target on shares of Arcutis Biotherapeutics from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Needham & Company LLC increased their price target on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Zacks Research cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. Finally, Mizuho dropped their price target on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.00.

View Our Latest Stock Report on Arcutis Biotherapeutics

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Arcutis Biotherapeutics Company Profile

(Get Free Report)

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.